Literature DB >> 2591469

Zero-order absorption and linear disposition of oral colchicine in healthy volunteers.

G Thomas1, C Girre, J M Scherrmann, P Francheteau, J L Steimer.   

Abstract

The pharmacokinetics of colchicine has been studied in nine healthy male volunteers after oral doses of 0.5, 1, and 1.5 mg as tablets. Plasma and urine samples were collected over 48 h and analysed for colchicine by radioimmunoassay. Individual colchicine concentration profiles in plasma and urine were well described by a two-compartment open model with zero-order input. Considering the absorption variables as specific to each experiment, the lag time (0-0.35 h) and duration (0.39-2.38 h) of absorption were found to be independent of dose, while the zero-order rate constant of absorption (k0) increased linearly with dose. Disposition variables were taken as common to the three experiments, except in six subjects in whom renal excretion varied significantly across experiments in a dose-independent manner. For seven subjects the terminal half-life was 19.4 h, the oral apparent volume of distribution at steady-state (Vss/f) was 691 l, and the oral systemic clearance (CL/f) was 33.1 l.h-1. In the two other subjects, the values were unreliable, but the estimated terminal half-life was greater than 48 h, Vss/f ranged from 1690 to 3480 l, and CL/f was in the range of the other subjects in 1 subject, and it was about 15 l.h-1 in the other. In the latter subject, these estimates, together with the observation that plasma concentration reached a plateau at 2 to 5 h after ingestion, suggest enterohepatic cycling of colchicine. Overall, the disposition of colchicine was linear in the dose range 0.5-1.5 mg, with a long terminal half-life, and absorption obeyed zero-order kinetics, with k0 proportional to dose.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2591469     DOI: 10.1007/bf00609430

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Pharmacokinetics of drugs subject to enterohepatic circulation.

Authors:  H S Chen; J F Gross
Journal:  J Pharm Sci       Date:  1979-06       Impact factor: 3.534

2.  Plasma levels of colchicine after oral administration of a single dose.

Authors:  S L Wallace; N H Ertel
Journal:  Metabolism       Date:  1973-05       Impact factor: 8.694

3.  A time-lag model for pharmacokinetics of drugs subject to enterohepatic circulation.

Authors:  J L Steimer; Y Plusquellec; A Guillaume; J F Boisvieux
Journal:  J Pharm Sci       Date:  1982-03       Impact factor: 3.534

4.  Bone marrow depression associated with acute colchicine toxicity in the presence of hepatic dysfunction.

Authors:  I B Boruchow
Journal:  Cancer       Date:  1966-04       Impact factor: 6.860

5.  A prospective trial of colchicine for primary biliary cirrhosis.

Authors:  M M Kaplan; D W Alling; H J Zimmerman; H J Wolfe; R A Sepersky; G S Hirsch; G H Elta; K A Glick; K A Eagen
Journal:  N Engl J Med       Date:  1986-12-04       Impact factor: 91.245

6.  Treatment of pustulosis palmaris et plantaris with oral doses of colchicine.

Authors:  M Takigawa; Y Miyachi; M Uehara; H Tagami
Journal:  Arch Dermatol       Date:  1982-07

7.  Colchicine in the treatment of cirrhosis of the liver.

Authors:  D Kershenobich; F Vargas; G Garcia-Tsao; R Perez Tamayo; M Gent; M Rojkind
Journal:  N Engl J Med       Date:  1988-06-30       Impact factor: 91.245

8.  Long-term evaluation of colchicine in the treatment of scleroderma.

Authors:  D Alarcon-Segovia; F Ramos-Niembro; G Ibanez de Kasep; J Alcocer; R P Tamayo
Journal:  J Rheumatol       Date:  1979 Nov-Dec       Impact factor: 4.666

9.  Colchicine kinetics in patients with familial Mediterranean fever.

Authors:  H Halkin; S Dany; M Greenwald; Y Shnaps; M Tirosh
Journal:  Clin Pharmacol Ther       Date:  1980-07       Impact factor: 6.875

10.  Management of necrotizing vasculitis with colchicine. Improvement in patients with cutaneous lesions and Behcet's syndrome.

Authors:  P G Hazen; B Michel
Journal:  Arch Dermatol       Date:  1979-11
View more
  5 in total

1.  Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects.

Authors:  M Rochdi; A Sabouraud; C Girre; R Venet; J M Scherrmann
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

2.  Colchicine suppresses neutrophil superoxide production in a murine model of gouty arthritis: a rationale for use of low-dose colchicine.

Authors:  E W Chia; R Grainger; J L Harper
Journal:  Br J Pharmacol       Date:  2008-02-11       Impact factor: 8.739

3.  Comparison of the efficacy of once- and twice-daily colchicine dosage in pediatric patients with familial Mediterranean fever--a randomized controlled noninferiority trial.

Authors:  Adem Polat; Cengizhan Acikel; Betul Sozeri; Ismail Dursun; Ozgur Kasapcopur; Nesrin Gulez; Dogan Simsek; Mehmet Saldir; Ipek Dokurel; Hakan Poyrazoglu; Sevcan Bakkaloglu; Ali Delibas; Zelal Ekinci; Nuray A Ayaz; Yasar Kandur; Harun Peru; Yasemin G Kurt; Safiye R Polat; Erbil Unsal; Balahan Makay; Faysal Gok; Seza Ozen; Erkan Demirkaya
Journal:  Arthritis Res Ther       Date:  2016-04-07       Impact factor: 5.156

4.  Colchicine for the treatment of COVID-19 patients: efficacy, safety, and model informed dosage regimens.

Authors:  Eleni Karatza; George Ismailos; Vangelis Karalis
Journal:  Xenobiotica       Date:  2021-04-12       Impact factor: 1.908

Review 5.  Immunomodulatory drug discovery from herbal medicines: Insights from organ-specific activity and xenobiotic defenses.

Authors:  Jue Shi; Jui-Hsia Weng; Timothy J Mitchison
Journal:  Elife       Date:  2021-11-15       Impact factor: 8.140

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.